Press Releases

Endonovo to Donate SofPulse® Units for Investigational Use to Evaluate Inhibition of Inflammatory Symptoms Associated with COVID-19

Download PDF

Los Angeles, CA, March 16, 2020 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company") today announced it will donate SofPulse® devices to Intensive Care Units and medical professionals for investigational use to evaluate SofPulse® PEMF technology’s inflammation reduction effect to determine potential efficacy in reducing symptoms of respiratory inflammation and distress in COVID-19 patients.

As of March 15th, 2020, over 160,000 worldwide cases of COVID-19 have been reported and the World Health Organization (“WHO”) has labeled the spread of this virus a pandemic. Medical researchers who have previously successfully studied SofPulse® in trials and clinical studies for reduction of pain and edema postoperatively, as well as for (TBI) Traumatic Brain Injury have identified an anti-inflammatory response through which SofPulse® technology may help to mitigate the severe respiratory inflammation observed in some COVID-19 patients.

A recent publication in the Journal of Biological Regulators and Homeostatic Agents proposes the role of inflammation in coronavirus infection

Endonovo Chief Medical Officer, Dr. Nev Zubcevik states, “COVID-19 has been shown to be causing a release of pro-inflammatory cytokines which contribute to overwhelming inflammation termed a "cytokine storm" in the respiratory system leading to worsened clinical outcomes. The SofPulse® Pulsed Electromagnetic Field device is FDA-cleared for post-operative management of pain and edema where clinical analysis has shown that the primary mechanism of action is noninvasive reduction of pro-inflammatory cytokine Interleukin 1 Beta and improvement of circulation in tissues. In clinical studies, SofPulse® PEMF technology is proven to reduce IL-1 beta by 275% at the 18-hour mark after surgery. This is the same interleukin response that has been implicated in the heightened inflammatory response resulting from the COVID-19 infection leading to increases in morbidity and mortality rates.” Dr. Zubcevik further states, “Although there is no clinical trial or test proving the efficacy of SofPulse® in treating respiratory inflammatory conditions, we have observed success in clinical trials using SofPulse® to mitigate the release of inflammatory response factors. In donating SofPulse® units to intensive care units for investigational use in treating patients who are severely ill from COVID-19, Endonovo and myself are hopeful that the SofPulse® can be utilized to help reduce the severity of inflammation symptoms in the lungs, much like it does in post-operative wounds, reducing morbidity and mortality and yielding faster recovery.” (

Alan Collier, Endonovo Chief Executive Officer comments, “We are optimistic that donating SofPulse® PEMF technology for investigational use and doing what we can do to help the US response to the COVID-19 pandemic will assist infectious disease units and medical professionals treating patients diagnosed with COVID-19 in a positive manner.” Collier further states, “Endonovo is not in a position to comment on the efficacy or possible benefits SofPulse® may provide against COVID-19 at this time. However, we believe the inflammation caused by Coronavirus may be inhibited by SofPulse®’s PEMF technology. Additionally, in all of the years that SofPulse® has been used, there have been no negative effects or contraindications from use of SofPulse® in any area tested or when applied during medical treatments. Endonovo wants to do its humanitarian duty by donating SofPulse® units for investigational use only to possibly help to reduce mortality rates as we fight this battle with COVID-19.”

Sofpulse® donations are only to hospitals treating patients in critical care. For more information contact Endonovo at:

Additional information regarding SofPulse® can be found at

About Endonovo Therapeutics Inc.

Endonovo Therapeutics is a commercial-stage developer of noninvasive wearable Electroceuticals® therapeutic devices. The Company's current portfolio of commercial and clinical-stage wearable Electroceuticals® therapeutic devices addresses wound healing, pain, post-surgical pain and edema, cardiovascular disease, chronic kidney disease, and central nervous system (CNS) disorders, including traumatic brain injury (TBI), acute concussions, post-concussion syndrome and multiple sclerosis. The Company's noninvasive Electroceutical® therapeutic device, SofPulse®, which uses pulsed short-wave radiofrequency at 27.12 MHz, has been FDA-cleared and CE marked for the palliative treatment of soft tissue injuries and post-operative pain and edema and has CMS national coverage for the treatment of chronic wounds. The Company's current portfolio of preclinical-stage Electroceuticals® therapeutic devices addresses chronic kidney disease, liver disease non-alcoholic steatohepatitis (NASH), cardiovascular and peripheral artery disease (PAD), and ischemic stroke. The Company's noninvasive, wearable Electroceuticals® therapeutic devices work by restoring key electrochemical processes that initiate anti-inflammatory and growth factor cascades necessary for healing to occur.

Safe Harbor Statement

This press release contains information that constitutes forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, trends, analysis, and other information contained in this press release including words such as "anticipate," "believe," "plan," "estimate," "expect," "intend," and other similar expressions of opinion, constitute forward-looking statements. Any such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from any future results described within the forward-looking statements. Risk factors that could contribute to such differences include those matters more fully disclosed in the Company's reports filed with the Securities and Exchange Commission. The forward-looking information provided herein represents the Company's estimates as of the date of the press release, and subsequent events and developments may cause the Company's estimates to change. The Company specifically disclaims any obligation to update the forward-looking information in the future. Therefore, this forward-looking information should not be relied upon as representing the Company's estimates of its future financial performance as of any date subsequent to the date of this press release.

Investor Relations Contact:
Endonovo Therapeutics, Inc.
Mr. Andrew Barwicki

Primary Logo

Source: Endonovo Therapeutics, Inc.